Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Efficacy and Safety of Treatment of Complex Idiopathic Fistula-in-Ano Using Autologous Centrifuged Adipose Tissue Containing Progenitor Cells: A Randomized Controlled Trial.

Ascanelli S., Zamboni P., Campioni D., Grazia Sibilla M., Chimisso L., Zollino I.

Randomized Controlled Trial with a reported sample of 58 on Chronic Wound, Autoimmune Research, published in Dis Colon Rectum (2021) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Dis Colon Rectum (2021)
Country
United States
Reported sample size
58
Source database
PubMed
PMID
34016825
DOI
10.1097/DCR.0000000000001924
NCT
NCT04326907

Abstract (original English)

Mesenchymal stem cells derived from adipose tissue have been successfully used to promote sphincter-saving anal fistula healing. The aim of this study was to evaluate the efficacy and safety of the use of autologous centrifuged adipose tissue in the healing process of cryptoglandular complex anal fistulas. This is a randomized controlled trial. This study was conducted at a single center. Patients with complex perianal fistulas not associated with Crohn's disease were included. Rectovaginal fistulas were not included. Patients were randomly allocated to receive treatment with centrifuged adipose tissue injection (experimental group) and without injection (control group) in combination with fistula surgery. The primary outcome was defined as the proportion of patients with complete fistula closure at 4 weeks (short-term outcome) and 6 months after surgery (long-term outcome). Healing was defined as when the external opening was closed with no perianal discharge on clinical assessment. The secondary outcome was safety that was evaluated by the analysis of adverse events up to 3 months after surgery. Pelvic MRI was performed at 3 months to assure safety and the accuracy of the clinical determination of healing. Postoperative pain, return to work/daily activities, persistent closure at 6 months, fecal incontinence, and patient satisfaction were evaluated. Fifty-eight patients who r

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueCase-Control StudiesFecal IncontinenceFemaleHumansInjections, SubcutaneousItalyMagnetic Resonance ImagingMaleMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research